timothy sykes logo
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal Thumbnail
G Google News

Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal

ELLIS HOBBS•UPDATED SEP. 29, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Summit Therapeutics Inc. stocks have been trading up by 21.12 percent following highly positive drug development and trial news.

Key Takeaways

  • AstraZeneca is putting $2B into Summit Therapeutics via convertible preferred stock at an implied $18.36 per share, a premium to recent SMMT trading, plus a broad ivonescimab collaboration.
  • Phase III HARMONi and HARMONi‑2 data show ivonescimab improves overall survival versus placebo plus chemo and versus pembrolizumab in NSCLC, backing a BLA with a 2026/11/14 PDUFA date.
  • Jefferies upgraded SMMT to Buy and hiked its price target to $25 from $15 ahead of HARMONi‑3 PFS data, signalling confidence even under less‑than‑perfect scenarios.
  • Akeso’s HARMONi‑GI1 biliary tract cancer trial showed ivonescimab beating durvalumab plus chemo on survival, PFS, and response rate, earning a Presidential Symposium slot at ESMO 2026.
  • Shares of Summit Therapeutics jumped about 15% in after‑hours trading after the AstraZeneca equity commitment, showing a strong immediate reaction from the market.

Candlestick Chart

Live Update At 09:19:16 EDT: On Tuesday, September 29, 2026 Summit Therapeutics Inc. stock [NASDAQ: SMMT] is trending up by 21.12%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SMMT is trading like a classic high‑expectation biotech. Over the past couple of weeks, Summit Therapeutics has swung from a close near $17.60 on 2026/09/04 up through the high $18s and then slid back toward the mid‑$15s by 2026/09/28. That retrace came even as bullish news piled up, which tells traders one thing: volatility is the norm here, not the exception.

On the fundamentals, SMMT is still a money‑losing clinical‑stage story. The latest quarterly report shows roughly $231.8M in net loss and negative operating cash flow of about $93.1M. Return on equity and assets are deeply negative, while revenue remains essentially zero. This is why traditional value ratios scream “expensive” — price‑to‑book near 19.8 and an enterprise value around $11.68B.

More Breaking News

But Summit Therapeutics also sits on about $238.6M in cash and carries very little debt, with a current ratio around 7. That balance sheet gives SMMT runway to keep funding trials until the AstraZeneca capital arrives. For traders, the message is clear: SMMT is a high‑beta catalyst vehicle tied to clinical and deal headlines, not to earnings or cash flow — yet.

Why Traders Are Watching SMMT Now

Traders are glued to Summit Therapeutics right now because the story just changed in a big way. AstraZeneca is stepping in with a $2B strategic equity investment, buying convertible preferred shares at an implied $18.36 per SMMT common share. That is roughly a 10% premium to recent trading levels. Big pharma does not pay a premium like that unless it sees real potential.

Beyond the check size, the structure matters. AstraZeneca and Summit Therapeutics are launching a broad clinical collaboration around ivonescimab, SMMT’s lead oncology asset. The two will test ivonescimab with AstraZeneca’s antibody‑drug conjugate sonesitatug vedotin and other cancer medicines across multiple tumor types, with AZ sponsoring and co‑funding studies. For SMMT traders, that reduces funding risk and execution risk at the same time.

The tape already reacted. After the AstraZeneca news, SMMT jumped about 15% in after‑hours trading, showing traders were under‑positioned for a deal of this size. Intraday five‑minute charts now show SMMT grinding in the high‑teens with repeated attempts to push above $19, reflecting tug‑of‑war between profit‑takers and new momentum buyers.

Under the hood of this partnership is a string of strong Phase III data. Updated HARMONi and HARMONi‑2 results show ivonescimab improving overall survival versus placebo plus chemo and even versus pembrolizumab in NSCLC, with consistent efficacy in both Asian and Western patients and no new safety signals. That is the engine behind the filed BLA and the 2026/11/14 PDUFA date — a clear, time‑stamped catalyst SMMT traders can anchor around.

Layer on Akeso’s positive data in biliary tract cancer and the high‑profile ESMO 2026 Presidential Symposium slot, and the SMMT pipeline looks more like a platform than a single‑trial bet. That is exactly the kind of shift that often precedes a multi‑month re‑rating in trading names like this.

Conclusion

Summit Therapeutics now sits at the crossroads of big money, big data, and big expectations. The $2B AstraZeneca deal validates ivonescimab as a global oncology contender and gives SMMT both cash and a heavyweight partner just as key Phase III programs head toward regulators. For active traders, that combination often drives multi‑leg moves — sharp spikes on news, consolidations, then fresh breakouts as the story spreads.

At the same time, the financials remind everyone what SMMT really is today: a cash‑burning biotech whose value rests on future approvals and commercial execution. Losses are large, revenue is absent, and metrics like price‑to‑book sit at lofty levels. That is normal for this kind of name, but it means every data readout and every regulatory milestone — including the 2026/11/14 PDUFA — can swing the chart hard in either direction.

The Jefferies upgrade to Buy, with a raised $25 target on SMMT ahead of HARMONi‑3, shows the Street leaning bullish on those milestones. But as Tim Sykes loves to remind traders, “The key is to trade like a sniper, not a machine gunner — wait for the best setups, then strike fast and manage risk relentlessly.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With Summit Therapeutics, that means respecting the hype, respecting the catalysts, and above all, respecting your stop. This coverage is strictly for educational and research purposes and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”